Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
CDE Coeur Mining Inc
NOV Nov Inc
GLDG GoldMining Inc
SOJC Southern Co
NYCB New York Community Bancorp Inc
USLM United States Lime & Minerals Inc
KAVL Kaival Brands Innovations Group Inc
GOVT iShares U.S. Treasury Bond ETF
IVW iShares S&P 500 Growth ETF
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.

Closing Price
$2.63
Day's Change
0.08 (3.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.67
Day's Low
2.49
Volume
(Heavy Day)
Volume:
926,675

10-day average volume:
737,322
926,675

Company Profile

Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. The Company is focused on the development of pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and a heterogeneous group of rare epilepsies known as developmental and epileptic encephalopathies (DEE). Its lead product candidate, Zygel (ZYN002 CBD Gel) is a cannabidiol (CBD) gel for FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare epilepsies known as DEE. Its clinical program for Zygel includes clinical trials evaluating Zygel in the treatment of behavioral symptoms of FXS, ASD and 22q and the reduction of seizures and the treatment of associated symptoms in patients with DEE syndromes.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.38x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

December 2021
Current Month
3.1M
Previous Month
3.0M
Percent of Float
7.84%
Days to Cover
5.0688 Days

Share Information

ZYNE is in a share class of common stock
Float
40.1M
Shares Outstanding
41.2M
Institutions Holding Shares
62
32.96%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Armando AnidoChmn.
  • Terri B. SebreePres.
  • James E. FickenscherCFO
  • Suzanne M. HanlonVP
  • Brian Rosenberger

Address

  • 80 W. Lancaster Avenue, Suite 300
  • Devon, PA 19333
  • Phone: (484) 581-7505
  • Fax: (302) 655-5049
  • http://zynerba.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.